Summary Minutes of the Oncologic Drugs Advisory Committee Meeting September 14, 2011 Location: FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (Rm. 1503), 10903 New Hampshire Avenue, Silver

First Page		Document Content
Oncology Deferiprone Oncologists Bristol-Myers Squibb Oncology Drug Advisory Committee Axitinib Medicine Prostate cancer Chemistry		Summary Minutes of the Oncologic Drugs Advisory Committee Meeting September 14, 2011 Location: FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (Rm. 1503), 10903 New Hampshire Avenue, Silver Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 100,73 KB Share Document on Facebook

	Uncertainty evaluation of image-based tumour control probability models in radiotherapy of prostate cancer using a visual analytic tool DocID: 1vnrm - View Document
	Abstract # 3991 Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond CellCentric DocID: 1vi4a - View Document
	Spring 2014 Issue YES TO LIFE YOUR OPTIONS FOR CANCER Dear Friends and Supporters, In the last Newsletter, we told you about our autumn London Seminar on prostate cancer, the first of our DocID: 1v4PI - View Document
	CANINE BLADDER CANCER by Deborah W. Knapp, DVM, Dipl. ACVIM Cancer of the urinary tract in dogs can affect the kidneys, ureters, urinary bladder, prostate, or urethra (see Figure 1). Within the urinary DocID: 1uUAX - View Document
	EDITORIAL Prostate cancer and selective serotonin reuptake inhibitors Alka Aggarwal Aggarwal A. Prostate cancer and selective serotonin reuptake inhibitors.Ann Histol Surg Pathol. 2017;1(1)5. DocID: 1uKru - View Document